Quick Answer
Tarsus Pharmaceuticals, Inc. reported Operating Income of -$70.97 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$70.97M | +41.1% |
| 2024 | -$120.57M | +15.8% |
| 2023 | -$143.16M | -128.3% |
| 2022 | -$62.71M | -415.9% |
| 2021 | -$12.16M | +55.0% |
| 2020 | -$27.00M | -528.2% |
| 2019 | -$4.30M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.53M | +42.3% | +34.5% |
| June 30, 2025 | -$22.18M | +33.4% | +15.6% |
| March 31, 2025 | -$26.28M | +30.3% | -4.4% |
| September 30, 2024 | -$25.16M | +38.5% | +24.4% |
| June 30, 2024 | -$33.30M | -1.5% | +11.6% |
| March 31, 2024 | -$37.68M | -51.0% | +7.9% |
| September 30, 2023 | -$40.94M | -78.7% | -24.7% |
| June 30, 2023 | -$32.82M | -528.3% | -31.5% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +41.1% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Tarsus Pharmaceuticals, Inc.’s operating income has declined by 1551.2% (from -$4.30 million to -$70.97 million).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: